Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-974-4 | CAS number: 101-77-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 961
- Report date:
- 1961
Materials and methods
- Principles of method if other than guideline:
- BASF-Test: Test substance was applied by gavage in a 1.25 - 2.5% aqueous traganth suspension. Mortality, clinical signs, and pathology of animals was investigated. Additionally, methemoglobin and Heinz bodies were investigated.
- GLP compliance:
- no
- Test type:
- standard acute method
Test material
- Reference substance name:
- 4,4'-methylenedianiline
- EC Number:
- 202-974-4
- EC Name:
- 4,4'-methylenedianiline
- Cas Number:
- 101-77-9
- Molecular formula:
- C13H14N2
- IUPAC Name:
- 4,4'-methylenedianiline
Constituent 1
Test animals
- Species:
- cat
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: see table 1
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: aqueous traganth suspension
- Details on oral exposure:
- 1.25 - 2.5% aqueous traganth suspension were used.
- Doses:
- 10, 25, 50, 100, 200, and 400 mg/kg bw
- No. of animals per sex per dose:
- 10: 1 male; 2 female
25: 0 male; 3 female
50: 1 male; 2 female
100: 6 male; 5 female
200: 2 male; 5 female
400: 1 male; 1 female - Control animals:
- no
- Details on study design:
- One application of 1.25 - 2.5% aqueous tragacanth suspension were used.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 50 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 10: 0/3
25: 1/3; 1 female after 6 days
50: 0/3
100: 7/11; 3 male; 4 female
200: 6/7; 1 male; 5 female
400: 2/2; 1 male; 1 female - Clinical signs:
- other: After treatment animals were atonic, staggering and mostly vomitting. Animals had mydriasis, showed no pupil reaction to light and had a reduced corneal sensibility. The animals were amblyopic or suffered from blindness. These chacteristics could be obse
- Gross pathology:
- Hepatotoxicity:
One day after treatment damage of the liver was observed with a disturbed excretion of bromosulphthaleine. Also the activity of serume glutamate-pyruvate-transaminase was disturbed. High bilirubin levels in urin and icterus were observed. Damage of liver functions seemed to be reversible, but occured beginning with 10 mg/kg bw.
Kidney:
High urea levels were observed in blood, accompanied with high protein, leukocytes, erythrocytes levels in urine. Additionally kidney epithelial cells and granulated cylinders were verified in urine. These characteristics also occured from the dose level 10 mg/kg bw. - Other findings:
- Ophthamologigal reevaluation revealed strong mydriasis with no or weak reactivity toward light pulses. Blindeness was diagnosed by unsecure motion of the animals. Animals partly exhibited a spastic constriction of arteries (diameter decreased to approx. half) 43 and 22 days following application of the test substance.
Any other information on results incl. tables
Table 1: Body weights of cats (at study initiation and determination), Met-Hb levels (in %), Heinz bodies (% erythrocytes) and mortalities (day after application).
Dose (mg/kg) |
Bodyweight (kg) |
Bodyweight (kg) |
Methaemoglobine (%) |
Dead after days |
Killed after day | Heinz bodies (%) | characteristic intoxication |
study init. |
end det. |
||||||
10 |
3.3 |
3.2 |
- |
- |
- | 15 | - |
2.7 |
2.6 |
- |
- |
- | 8 | - | |
2.8 | 2.6 | - | - | - | 9 | - | |
25 | 2.5 | 2.5 | - | - | 29 | 28 | mydriasis up to blindness, nephrosis |
2.3 | 2.0 | - | - | 31 | 30 | mydriasis up to blindness, mild liver and kidney damage | |
2.6 | 2.2 | - | 6 | 24 | mydriasis up to blindness, mild ikterus | ||
50 | 2.6 | 2.4 | - | - | 54 | 47 | mydriasis up to blindness, mild hepatitis and nephrosis |
2.2 | 2.0 | 9 | - | 54 | 41 | mydriasis up to blindness, hepatitis | |
2.2 | 2.1 | 11 | - | 43 | 76 | mydriasis up to blindness | |
100 | 2.5 | 2.2 | - | - | - | - | mydriasis up to blindness, ikterus |
3.3 | 3.1 | 12 | 5 | 14 -73 | mydriasis up to blindness, ikterus, liver and kidney damage | ||
2.3 | 2.2 | - | 4 | - | mydriasis up to blindness (?), ikterus, mild kidney damage | ||
2.5 | 2.3 | - | 2 | - | mydriasis up to blindness, kidney damage | ||
3.9 | 3.9 | 13 | 2 | 27 -67 | mydriasis up to blindness, mild ikterus, mild liver and kidney damage | ||
3.6 | 3.0 | 11 | - | 71 | 26 -45 | mydriasis up to blindness, nephrosis | |
3.1 | 2.3 | - | - | 71 | 10 -94 | mydriasis up to blindness, nephritis and nephrosis | |
3.3 | 2.9 | - | - | 98 | 35 -46 | mydriasis up to blindness, nephritis | |
2.5 | 2.3 | 17 | 2 | 35 -46 | mydriasis up to blindness, kidney damage | ||
2.9 | 2.7 | - | 1 | - | mydriasis up to blindness, mild ikterus, | ||
2.6 | 2.4 | 11 | 3 | 18 -41 | mydriasis up to blindness, mild ikterus, liver and kidney damage | ||
200 | 2.9 | 2.6 | - | 1 | - | mydriasis up to blindness, ikterus, kidney damage | |
1.7 | 1.6 | 15 | 3 | 71 | mydriasis up to blindness, severe ikterus, liver and kidney damage | ||
2.9 | 2.4 | - | 2 | - | mydriasis up to blindness, mild ikterus, kidney damage | ||
3.6 | 3.1 | - | - | - | 12 -83 | mydriasis up to blindness | |
2.8 | 2.8 | - | 1 | - | mydriasis, | ||
3.3 | 3.0 | - | 2 | - | mydriasis up to blindness, | ||
2.8 | 2.6 | - | 4 | - | mydriasis up to blindness, ikterus, liver/kidney damage | ||
400 | 3.5 | 3.2 | - | 2 | - | mydriasis, | |
2.7 | 2.7 | - | 3 | 6 -24 | mydriasis, ikterus, liver/kidney damage |
Applicant's summary and conclusion
- Interpretation of results:
- Category 3 based on GHS criteria
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.